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KAJIAN INTERAKSI ANTARA TRUNKAT ONKOPROTIN HPV16 /18 E7 
DENGAN KOMPLEKS FAKTOR TRANSKRIPSI CTCF/YB-1 
 
ABSTRAK 
 Human papillomavirus (HPV) adalah agen etiologi kanser serviks 
dimana HPV16 dan HPV18 tergolong dalam kumpulan HPV berisiko tinggi. Kajian 
terdahulu mendedahkan interaksi antara onkoprotin HPV16/18 E7 dengan kompleks 
faktor transkripsi CTCF/Yb-1. Interaksi ini menyebabkan ekspresi c-myc meningkat 
dengan ketara yang membawa kepada percambahan sel. Dengan membahagikan 
HPV16 E7 dan HPV18 E7 kepada saiz yang lebih kecil, lokasi tepat di mana 
interaksi terhadap CTCF/Yb-1 dapat diketahui. Hal ini akan jelas mencirikan 
interaksi biokimia dan memberi pengetahuan yang lebih baik terhadap interaksi 
tersebut. Siri trunkat HPV16 E7 dan HPV18 E7 telah dihasilkan melalui tindak balas 
berantai polimerase, berdasarkan analisis kehidrofobian. Semua produk trunkat HPV 
E7, CTCF-Zn dan Yb-1 CSD telah diklon ke dalam vektor pET16bSH3 dan 
diekspres di dalam E. coli BL21 (DE3).  Interaksi protin-protin antara trunkat 
HPV16/18 E7 dengan kompleks CTCF/Yb-1 telah dianalisa melalui ujian Pull-down. 
HPV16 E7 dan HPV18 E7 jujukan penuh telah digunakan sebagai kawalan. Protin-
protin trunkat HPV16 E7 dan HPV18 E7 telah berjaya diekspres dan dibersihkan. 
Ujian Pull-down menunjukkan interaksi antara CTCF/Yb-1 dengan HPV16 dan 
HPV18 E7 jujukan penuh. Walau bagaimanapun, domain-domain trunkat HPV16 E7 
dan HPV18 E7 tidak menunjukkan sebarang interaksi sama ada dengan CTCF-Zn 
mahupun Yb-1 CSD. Pertamanya, ketidakbolehan domain trunkat untuk berinteraksi 
dengan protin lain mungkin kerana lipatan protin dimer yang salah. Mutasi kepada 
xix 
 
protin asal mungkin menyingkirkan interaksi hidrofobik dan mengakibatkan 
degradasi proteolisis. Hal ini menyebabkan struktur asli menjadi kurang stabil. 
Keduanya adalah kerana struktur protin dimer E7 itu.  Pemangkasan tanpa domain 
CR1/CR2 atau domain terminal-C akan menghapuskan ikatan zink. Tanpa zink, E7 
tidak dapat membentuk dimer seterusnya mengganggu interaksi dengan protin yang 
berpotensi menjadi pasangan. Kesimpulannya, HPV16 E7 dan HPV18 E7 tidak 
boleh dipendekkan berdasarkan profil kehidrofobian sahaja dimana ia menjejaskan 
lipatan dan kestabilan protin itu. Trunkasi HPV16 E7 dan HPV18 E7 yang 
kekurangan terminal -N atau –C mungkin menyebabkan kestabilan protein asal 
berkurangan, seterusnya menganggu interaksi protin-protin.  
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INTERACTION STUDIES BETWEEN TRUNCATED HPV16/18 E7 
ONCOPROTEIN WITH CTCF/YB-1 TRANSCRIPTION FACTORS 
COMPLEX 
 
ABSTRACT 
Human Papillomavirus (HPV) is the aetiology agent of cervical cancer where 
HPV16 and HPV18 are the high-risk group of HPV. Previous study had revealed the 
interaction between HPV16/18 E7 oncoprotein with CTCF/Yb-1 transcription factors 
complex. This interaction resulted in marked enhancement of c-myc expression that 
leads cell proliferation. By truncating HPV16 E7 and HPV18 E7 into smaller size, 
the exact location of interaction towards CTCF/Yb-1 can be known. This will clearly 
characterise the interaction biochemically and provide a better insight of the 
interaction. Series of truncated HPV16 E7 and HPV18 E7 had been produced by 
polymerase chain reaction (PCR) based on hydrophobicity analysis. The truncated 
HPV E7 products, CTCF-Zn domain and Yb-1 cold shock domain (CSD) had been 
cloned into pET16bSH3 vector and expressed in E. coli BL21 (DE3). The protein-
protein interaction between truncated HPV16/18 E7 and CTCF/Yb-1complex had 
been analysed via Pull-down Assay. HPV16 E7 and HPV18 E7 full length had been 
used as control.  The series of truncated HPV16 E7 and HPV18 E7 proteins were 
successfully expressed and purified. Pull-down assay displayed interaction between 
CTCF/Yb-1 and HPV16/18 E7 full length. However, the truncated domains of 
HPV16 E7 and HPV18 E7 did not form any binding with neither CTCF-Zn nor Yb-1 
CSD. Firstly, the inability of truncated domain to interact with other protein might be 
due to false folding of the dimer protein. Mutation to a wild type protein might 
xxi 
 
remove the hydrophobic interaction and cause proteolytic degradation. Thus, the 
native structure becomes less stable.   Secondly, it might be due to structure of E7 
dimer protein. Truncation that lack of CR1/CR2 domain or C-terminal domain will 
abolishes zinc binding. In the absence of zinc, E7 cannot form dimer thus disrupting 
interaction with potential protein partner.  Therefore, we concluded that HPV16 E7 
and HPV18 E7 cannot be truncated based on hydrophobicity profile only due to 
protein folding and stability. The truncation of HPV16 E7 and HPV18 E7 that lack of 
N- or C-terminal might reduce the stability of the native protein thus disrupt the 
protein-protein interaction.  
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CHAPTER ONE 
INTRODUCTION 
 
1.1 Human papillomavirus and cervical cancer 
Human papillomavirus (HPV) is a sexually transmitted virus that comprises 
of circular double stranded DNA with an approximately size of 8 kb. Almost 150 
genotypes have been identified so far and about 40 of them infect genital mucosa 
(Schiffman et al., 2011). These HPVs caused more than 90% of all cervical cancer 
cases (Muñoz et al., 2003) with an estimated 100% of cervical cancer cases in United 
Kingdom (Cancer Research UK, 2012). They are categorized into two groups; low-
risk and high-risk, based on their presence in malignant lesion of the cervix. The 
low-risk HPVs such as HPV6 and HPV11 formed localized benign warts and these 
warts do not undergo malignant progression even without treatment while high-risk 
HPVs such as HPV16 and HPV18 can cause cervical carcinoma. According to World 
Health Organization (WHO, 2015), HPV16 and 18 associated with 70% of cervical 
cancers and precancerous cervical lesions. In 2012, about 445,000 new cervical 
cancer cases are diagnosed worldwide, especially in women living in less developed 
regions. It remains as the second most common cancer among women worldwide and 
the third most common cancer among Malaysian women (MoH Malaysia, 2007, 
WHO, 2015). High-risk HPV infections also associated with anal cancer, a subset of 
head and neck cancers (Nair and Pillai, 2005) and a subset of vulvar, vaginal and 
penile cancers (Steenbergen et al., 2005).  
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1.2 HPV genome organization and life cycle 
The HPV genome can be separated into three regions; an early (E) region, a 
late (L) region and a non-coding long control region (LCR). The early region 
encodes non-structural proteins; the late region encodes structural proteins while 
LCR controls viral replication and gene expression. They are labelled as E or L based 
on their expression specified in early or late stage of epithelium differentiation, and 
numbered based on size. As the number increase, the corresponding open reading 
frame (ORF) becomes smaller. There are six ORFs expressed early in the epithelial 
differentiation marked as E1, E2, E4, E5, E6 and E7 and two late ORFs; L1 and L2. 
The HPV infection was established by maintaining the expression of the viral 
genome at the basal layer of the epithelium. The viral life cycle goes through success 
stages of genome amplification, virus assembly and virus release throughout the 
basal epithelial cells differentiation. The virus released simultaneously cause changes 
in gene expression pattern of early to late genes including L1 and L2 that formed the 
viral capsid where L1 is the major capsid protein while L2 functions as a link to the 
plasmid DNA (Schiffman et al., 2007) .  The HPV genome organization and the 
general function of their respective proteins are illustrated in Figure 1.1. 
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Figure 1.1: HPV16/18 genome organization and the general function of their 
respective proteins. The HPV genome can be divided into three parts; 
early (E) region, a late (L) region and non-coding long control region 
(LCR). Adapted from Schiffman et al. (2007). 
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The E6 and E7 oncogenes are associated with almost all cervical carcinomas 
cases. These viral proteins are constantly expressed in the tumours and they are 
necessary for both induction and maintenance of the transformed phenotype. Mostly, 
the carcinogenesis of human cells is caused by inactivation of tumour suppressor p53 
and/or retinoblastoma protein (pRB) where E6 associates with p53 and E7 associates 
with pRB (Narisawa-Saito and Kiyono, 2007). Among these two viral proteins, the 
E7 protein was marked as the main transforming activity of high-risk HPVs 
(McLaughlin-Drubin and Münger, 2009) where E7 alone is sufficient to immortalize 
human epithelial cell. Therefore E7 is considered to be a target of immunotherapy for 
cervical cancer (Fernando et al., 1995). 
 
1.3 HPV E7 oncoprotein 
1.3.1 Biochemical characterization of E7 oncoprotein 
The E7 oncoprotein was identified as the first oncogene of high-risk HPV 
(Vousden et al., 1988). E7 is a small polypeptide composed of nearly 100 amino acid 
residues. The intrinsic enzymatic activity of this protein is not known but it has 
phosphoprotein characteristics; a consensus casein kinase II (CK II) phosphorylation 
site in their amino terminal. Their amino terminal also have a region of sequence 
homology with some conserved region (CR) 1 and entire CR2 of adenovirus (Ad) 
E1A, and related sequences in simian vacuolating virus 40 T antigen (SV40 T) 
(Figge et al., 1988, Phelps et al., 1988). These two conserve regions play important 
roles in transforming activities of cancerous cells by HPV E7 (Watanabe et al., 1990, 
Phelps et al., 1992, Jewers et al., 1992). Besides that, CR2 domain consists of a 
LXCXE motif (Leucine, Cysteine and E is glutamic acid) that is important for 
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association of E7 protein with pRB (Münger et al., 1989). However, some studies 
claim that C-terminal E7 domain also contains pRB binding site but with low affinity 
(Patrick et al., 1994, Liu et al., 2006). Adjacent to Adjacent to the LXCXE motif is a 
consensus casein kinase II (CK II) that involve in phosphorylation of E7 protein 
(Firzlaff et al., 1989). The carboxyl terminal of E7 contains a zinc-binding domain; 
comprise of two copies CXXC motif separated by 29 amino acid (Barbosa et al., 
1989). This domain associates in dimerization of E7 in which it found to be involved 
in metal binding and mediate direct interaction with several proteins partner 
(Clemens et al., 1995,  Münger et al., 2001). These important regions of E7 were 
illustrated in Figure 1.2. Moreover, a study by Alonso et al. (2002) had revealed the 
oligomerization properties of E7 where monomers, dimers and tetramers were 
detected.  
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Figure 1.2: Illustration of important regions in HPV16 E7. The N-terminal 
consists of CR1 (green) and CR2 (red) where CR2 contains 
the core pRB-binding site (LXCXE motif), while the C-
terminal (blue) comprises of a metal binding motif (two copies 
of CXXC motifs spaced by 29 amino acids). Adapted from 
Münger et al. (2004). 
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1.3.2 HPV E7 life cycle and cellular target 
The HPV E7 protein is consistently expressed in HPV positive cervical 
carcinomas. During carcinogenic progression, the HPV genome frequently integrates 
into a host cell chromosome. These oncogenic activities of high-risk HPV E7 reflect 
their function during the viral life cycle where it intimately associated with the 
differentiation process of the infected epithelial cell. In order to establish a persistent 
infection, the HPV genomes were maintained at low copy number where it 
exclusively occurs in the terminally differentiated layers of epithelium (reviewed in 
Lee and Laimins, 2007).  
The most important cellular target for HPV E7 in cell transformation is pRB 
tumour suppressor. The pRB is a family of closely linked protein including p107 and 
p130. It was found bind to E2F and inhibit transcriptional activation function. E2F is 
a heterodimer transcription factor that involved in regulation of G1/S phase of cell 
cycle progression. In normal cells, the hypophosphorylated pRB protein can bind to 
E2F-family transcription factor. Then, the pRB-E2F complex down-regulated the 
transcription of certain genes necessary for DNA synthesis and cell cycle progression 
(Dyson, 1998). When G1 cyclin-dependent kinases phosphorylate pRb, E2F will be 
released and cause the cell cycle to progress into S phase. In cancer cells, E7 bind to 
unphosphorylated pRB via LXCXE motif and it prematurely induces cells to enter S 
phase by disrupting pRB-E2F complexes (Yim and Park, 2005). Thus, lead to 
abnormal cell progression. The high-risk HPVs bound to pRB with higher affinities 
compared to low-risk HPVs (Münger et al., 1989). Furthermore, A. Suhrbier has 
found that cleavage of pRB by calcium activated cysteine protease calpain was 
promoted by E7 protein. This cleavage is necessary before E7 can stimulate the 
proteasomal degradation of pRB (Narisawa-Saito and Kiyono, 2007). Figure 1.3 
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summarized how HPV E7 binds with pRb interfering with the normal functions of 
the tumour suppressors. 
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Figure 1.3: Life cycle of pRB-E2F complex disrupted by HPV E7. E7 
interfering with the normal functions of the pRB tumour 
suppressors. Adapted from Yim and Park (2005). 
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In addition, E7 also has different targets that associated with cellular 
transformation as it can override the growth inhibitory activities of the cyclin 
dependent kinase inhibitors, including p21
CIP1
 and p27
KIP1
 ( Münger et al., 2004). 
Besides that, cervical carcinoma cells that were infected with HPV E7 showed a 
significant increase in the level of c-myc expression (Gewin and Galloway, 2001, Oh 
et al., 2001, DeFilippis et al., 2003). This finding showed that cervical carcinoma 
was tightly associated with c-myc gene amplification especially when infected with 
HPV16 where c-myc gene increased according to the grade lesion of cervical 
carcinoma (Abba et al., 2004). Furthermore, the cells transfected with E7 protein 
also significantly increases the level of c-myc gene expression (Liu et al., 2007). 
These findings have confirmed that the E7 oncoprotein plays an important role in the 
activation of c-myc gene, but the mechanism of action is still unknown. 
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1.4 Transcription factors 
1.4.1 CTCF protein 
 CTCF is also known as CCCTC-binding factor, is highly expressed and 
conserved in eukaryotes. It is well-known for its 11 zinc fingers (ZFs) that perform 
various regulatory functions in the cell. It was first isolated by Lobanenkov (1990) as 
a transcriptional repressor that bind to 50-60 bp sequence within the promoter region 
of chicken c-myc gene (Klenova et al., 1993). Following that, CTCF was identified 
bind to numerous different sequences in the mouse, avian and human c-myc 
promoter (Filippova et al., 1996, Klenova et al., 2001). The structure of CTCF can 
be divided into three parts; an amino (N) terminal domain, a central zinc (Zn) domain 
(with 11 zinc fingers) and a carboxyl (C) terminal domain (Vostrov et al., 2002). The 
Zn domain displays almost 100% homology between mouse, chicken and human. 
The ZFs can be classified into two types; the first ten ZFs are 30 amino acid residues 
comprised of a pair of cysteine and a pair of histidine (C2H2-type) that is separated 
by 12 amino acids while the 11
th
 ZF is the C2HC-type  (Ohlsson et al., 2001). The 
structural features of CTCF were illustrated in Figure 1.4.  
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Figure 1.4: Schematic illustration of CTCF structural features adapted from 
Klenova et al. (2002). Each ZF contains a pair of cysteine residues 
and a pair of histidine, 12 amino acids apart except for the 11
th
 ZF 
(C2HC-type). The Zn domain displays almost 100% homology 
between mouse, chicken and human. Certain sets of ZFs is necessary 
for the CTCF binding to a target sequence but unnecessary to form 
binding with others. 
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CTCF found in nearly 65,000 sites in the genome of mammals in which 15% 
of them bind on the promoter proximal. Therefore, it was concluded that CTCF is 
capable of managing the architecture of the chromosome by binding to different 
sites. In addition, CTCF also has functions in the regulation of gene expression 
through repression or activation promoter, the regulation of distant chromatin 
interactions and the insulation of enhancers or silencer (Phillips and Corces, 2009).  
CTCF is involved in various roles in gene regulation including context-
dependent promoter activation or repression such as regulation of c-myc gene 
expression. It was found to bind the c-myc promoter and down-regulated the 
expression. Besides that, CTCF was found to associate with Negative protein 1 
(NeP1) at a modular silencing element, 2.4 kb upstream of the chicken lysozyme gene 
(Baniahmad et al., 1990, Burcin et al., 1997). The CTCF was also reported as a 
transcriptional repressor of NeP1 based on the observation that the chicken lysozyme 
silencer containing a CTCF-binding site adjacent to a thyroid hormone response 
element, was synergistically decrease the reporter gene expression (Kohne et al., 
1993). However, the full composite element displayed inconsistent results dependent 
on the cell line used. Therefore, it had been concluded that CTCF binding site has 
only minimal impact on the reporter gene expression. Following analysis had 
identified that CTCF also involve in activation of gene expression. In other study, 
Vostrov and Quitschke (1997) identified CTCF was bind immediately to upstream 
Amyloid Protein Precursor (APP) and up-regulate the gene expression. In this work, 
transgene assays were used to support the conclusion that CTCF also can serve as a 
transcriptional activator. Besides that, CTCF also involved in activation of the APP 
gene where it binds to the promoter region (APPβ) and up-regulates the gene 
transcription (Chen et al., 2013). 
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Using chromatin immunoprecipitation with microarrays (ChiP-chip), it was 
found that CTCF and cohesin work together to regulate a function (Wendt et al., 
2008). CTCF co-localize with cohesin and cause changes to chromatin structure and 
control gene regulatory elements. Cohesin is a protein complex that regulates 
stabilization of chromatin loops, gene transcriptional and DNA repair (Kagey et al., 
2010, Faure et al., 2012). Usually, cohesin does not form binding with DNA but it 
was found associated with CTCF (Stedman et al., 2008). CTCF leads cohesin to its 
binding sites and cohesin helps CTCF to perform its insulator function. Hence, 
sequence-specific cohesin binding is dependent on CTCF but CTCF is not dependent 
on cohesin for its function (Wendt et al., 2008). The CTCF-cohesin complexes 
sustain the chromatin structures by co-localizing at various sites across the genome, 
such as Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) locus. At 
CTFR locus, CTCF formed complex with cohesin and created a chromatin loop that 
cause enhancer to reach promoter and activate transcription. Immediately upon 
knock-down of CTCF, the chromatin structure of CTFR locus was influenced, 
resulting in enhancement of gene expression (Gosalia et al., 2014).  
 Furthermore, CTCF was found to play an important role as an insulator. An 
insulator is a DNA sequence that suppresses gene activation by inhibiting enhancer 
from activating promoter (Herold et al., 2012). β-globin locus is the first individual 
locus that found in the discovery of CTCF’s function. Chung et al. (1993) had found 
that chicken β-globin locus can block the enhancer activity where a 42 bp fragment 
had been identified responsible for it. The fragment was found to be the CTCF-
binding site thus suggesting that CTCF plays a role in the insulation activity (Bell et 
al., 1999). Moreover, CTCF assist in formation of chromatin loops that incorporate 
β-globin gene and the locus control. During chromatin loops formation, β-globin 
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sites are relocated and blocked the enhancer signals thus repressed the gene 
transcription (Splinter et al., 2006).   
Another significant locus is the imprinted H19/Igf2 locus. The H19 gene is 
expressed exclusively from the maternal chromosome and Igf2 genes are expressed 
exclusively from the paternal chromosome. They are far apart from each other where 
the imprinting control region (ICR) lies between them (Pidsley et al., 2012). This is 
situated between 7 and 9 kb downstream of the H19 gene and 90 kb downstream of 
the Igf2 gene. This region contains four CTCF-binding sites. On the maternal 
chromosome, the CTCF formed binding with unmethylated ICR. This binding 
blocked the interaction between H19-proximal enhancer and Igf2 promoter thus 
inactivated Igf2. However, CTCF cannot bind the paternal ICR due to methylation, 
causing the H19 enhancer to activate Igf2 (Hark et al., 2000). CTCF binding can 
formed various chromatin loops integrating specific alleles with enhancers and 
promoters at the maternal ICR (Yoon et al., 2007).  
  Moreover, subsequent analysis revealed that CTCF helps in long-range 
chromosomal interaction via looping. CTCF was found helps in interchromosomal 
interaction formation by co-localizing the H19/Igf2 locus on chromosome 7 with the 
Wsb1/Nf1 locus on chromosome 11. When CTCF was knocked down, no 
interchromosomal interaction formed thus cause changes in Wsb1/Nf1 gene 
expression (Ling et al., 2006). Furthermore, CTCF-binding sites are found at both 
active and inactive domain boundaries (Cuddapah et al., 2009), and some are situated 
at the borders of the lamina-associated domains. The enrichments of CTCF binding 
at the lamina-associated domain boundaries suggested that CTCF has a role in 
shaping the three-dimensional chromatin organization (Guelen et al., 2008).   
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 Meanwhile, CTCF can bind to numerous protein partners. The DNA-binding 
proteins that form complex with CTCF are include Y-box binding protein 1 (Yb-1) 
(Chernukhin et al., 2000), Kaiso (Defossez et al., 2005), regulatory factor X (RFX) 
and MHC class II transactivator (CIITA) (Majumder et al., 2006) and Yin and yang 
1 (YY1) (Donohoe et al., 2007). Among these proteins, Yb-1 interacts with CTCF-
Zn domain and cooperates with CTCF in transcriptional repression of c-myc gene 
(Chernukhin et al., 2000, Balakrishnan, 2008). The CTCF-Zn domain is capable of 
binding either to DNA or protein, unlike other multi-ZF proteins that bind to DNA 
only or protein only.  
 
1.4.2 Yb-1 protein 
The multifunctional Y-box-binding (Yb) proteins are characterized by a 
highly conserved nucleic acid binding domain, termed cold-shock domain (CSD). It 
is widely distributed among bacteria, plants, animals and human (Wolffe et al., 
1992). These proteins bind to DNA containing Y-box or inverted CCAAT box in the 
promoter region of various eukaryotic genes and regulate gene expression. Previous 
reports showed that the Yb-1 protein was the most responsive to DNA damage, drug 
treatment, stress-related stimuli including ultra-violet (UV) irradiation, anti-cancer 
agents and heat in cancer cells in vitro (Ito et al., 2012, Wang et al., 2012).  
Y-box binding protein 1 (Yb-1) was named in 1988 when transcription 
factors were found binding to Y-box motif of major histocompatibility complex 
(MHC) class II gene (Didier et al., 1988). Y-box proteins can be divided into three 
subfamilies. The first subfamily is Yb-1 that includes human Yb-1, rabbit p50, 
chicken-Yb-1, bovine EFI-A, mouse MSY-1 and others. It contains 100% homology 
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with DNA binding protein B (dbpB). These proteins have characteristic of somatic 
cells that perform various functions and they are the most studied ones. The second 
subfamily is Yb-2 subfamily, includes protein mouse MSY-2 and FRGY2 (p54/56). 
These proteins also known as dpbC and contrin, and they are specific for germ cells. 
Finally is the Yb-3 subfamily, contains mouse MSY-3 and human dpbA (csdA) 
protein. These proteins supposed were synthesized during embryonic development 
and disappeared by the moment of birth. However, Yb-3 mRNA can be detected in 
some tissues of adult organism (Mastrangelo and Kleene, 2000).  
 The human Yb-1 gene is located in the first chromosome (1p34) where it 
consists of 19 kb nucleotides including eight exons. After splicing, the Yb-1 mRNA 
has length about 1,500 bp only encoding 43 kDa protein (Makino et al., 1996). The 
structure of Yb-1 is comprised of three domains; N-terminal domain that contains 
high content of alanine and proline (A/P domain), CSD domain and elongated C-
terminal domain containing alternating clusters of positively and negatively charged 
amino acid residues (Wolffe, 1994). The amino acid sequences of proteins from 
various subfamilies had demonstrated that their CSDs are identical by more than 
90%, while in other parts of the molecules, no significant homology is observed. It 
was discovered that the amino acid sequence of dbpB is completely identical to Yb-
1, and dbpA is homologous to it by 46%. The Yb-1 and dpbA have 44% sequence 
identical to Cold shock protein A (CspA) from Escherichia coli (Kudo et al., 1995). 
The three-dimensional (3D) structures of Yb-1 CSD and CspA turned out to be very 
close to each other and they consist of five β-strands packed antiparallel in a β-barrel. 
The CSD has the so-called RNA recognition motifs, RNP-1 and RNP-2 that involve 
in specific and non-specific interactions with DNA and RNA. The presence of a CSD 
is a specific feature of Y-box binding protein that allows them attribute to a wider 
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group of proteins containing a CSD (Eliseeva et al., 2011). The structural 
organization of Yb-1 and the difference between structure Yb-1, Yb-2 and Yb-3 were 
illustrated in Figure 1.5. 
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Figure 1.5: The domains of Y-box binding proteins subfamilies. Adapted from 
from Eliseeva et al. (2011).  
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In both somatic and germ cells, Yb-1 protein act as the major translational 
repressor and/or mRNA chaperones of mRNA-protein complexes (mRNPs) in the 
cytoplasm. It is primarily localized in the cytoplasm but in response to physical and 
environmental signals, Yb-1 translocate into the nucleus. Within the nucleus, the Yb-
1 protein has been involved in major nucleus activities such as DNA repair, pre-
mRNA splicing and transport, and transcriptional regulation. By passing from the 
cytoplasm to the cell nucleus, Yb-1 also activates transcription of several protective 
proteins including proteins that provide multidrug resistance of cells. It also enhances 
resistance of cells to xenobiotics and ionizing radiation when involved in DNA repair 
in the nucleus (Eliseeva et al., 2011). Therefore, Y-box proteins have been suggested 
as multifunctional coordinators of gene expression in both nucleus and cytoplasm 
(Wang et al., 2012). 
 The Yb-1 protein has broad functions in nucleic acid-binding properties. It 
can bind to both DNA- and RNA-binding protein that has properties of a nucleic acid 
chaperone, and it interacts with a great variety of other proteins. It shows a higher 
affinity for single stranded regions of DNA and RNA and markedly decreases the 
melting temperature of double helicases. Yb-1 has a higher affinity for damaged 
DNA structure and promotes DNA repair. During transcription, Yb-1 binds to pre-
mRNA on chromosomes and accompanies mRNA molecules all the way through 
their life. In the cell nucleus, Yb-1 performed alternative splicing of pre-mRNA. In 
the cell cytoplasm, almost all Yb-1 molecules are associated with translated or non-
translated mRNAs, determining their functional activity, stability and localization of 
translationally active mRNAs on actin skeleton. Thus, Yb-1 is involved not only in 
DNA- and mRNA-dependent processes, but in all steps of mRNA bio-genesis and 
functioning as well (Skabkin et al., 2006).  
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Besides that, Yb-1 content was found increased in cancer cells.  In some 
studies, Yb-1 can be considered as an oncoprotein that stimulate cell proliferation 
and promotes metastasis, but in other studies showed that Yb-1 can be a tumour 
suppressor in a number of cases.  Therefore it is suggested to be one of the most 
indicative markers for cancer therapy (Dahl et al., 2009, Lasham et al., 2013). Yb-1 
can give implication in the activation of transcription of c-myc gene where it binds to 
the CT-rich sequence in the promoter region, results in docking of core transcription 
factors and RNA polymerase II. Yb-1 protein is also known to interact with diverse 
range of proteins including transcription factors, viral proteins, repair proteins and 
actin filaments. One of the interacting proteins is CTCF transcription factor. This 
Yb-1/CTCF interaction was found to regulate c-myc gene expression (Chernukhin et 
al., 2000, Kohno et al., 2003). 
 
1.4.3 Effect of CTCF/Yb-1 complex towards c-myc oncogene and interaction 
with HPV16 E7 and HPV18 E7 
 The dysregulation of cell signalling and cell proliferation is commonly 
caused by inactivation of tumour suppressor genes and over-expression or mutation 
of proto-oncogenes. Activation of some oncogenes has been associated with many 
cancer cells including cervical carcinoma cells (Golijow et al., 2001, zur Hausen, 
2000, Mouron et al., 2000). The c-myc gene has been found associated in many solid 
tumours and various human cell lines (Riou et al., 1990). The c-myc is a proto-
oncogene and the cellular homologous of the v-myc transforming gene that encodes a 
helix-loop-helix leucine zipper domain transcription factor (Colby et al., 1983). The 
c-myc over-expression is a common event in cervical carcinoma (Iwasaka et al., 
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1992) and low-level c-myc gene amplification often found in HPV infected cases. 
This outcome indicates that HPV may has a critical biological impact on the 
development and progression of carcinomas of the uterine cervix since HPV-
associated cervical carcinomas can allow frequent alteration of c-myc gene (Zhang et 
al., 2002). Moreover, the integration of HPV sequences close to the c-myc locus has 
been found in some cervical cell lines, suggesting a synergistic role for HPV and c-
myc gene in the development of cervical carcinoma (Nair et al., 1998).  
 Yb-1 multifunctional factor was found to interact with CTCF and are likely to 
play multiple roles in regulation of major cellular process.  CTCF was known to bind 
promoter region of c-myc gene (Lobanenkov et al., 1990) and this interaction might 
affect c-myc expression. Expression of Yb-1 alone had no effect on c-myc reporter 
activity but co-expression of Yb-1 with CTCF resulted in a marked enhancement of 
CTCF-dependent transcriptional repression (Chernukhin et al., 2000). This binding 
was illustrated in Figure 1.6.  
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Figure 1.6:  Effect of CTCF/Yb-1 complex on c-myc gene. Yb-1 CSD formed 
complex with ZFs of CTCF on promoter region of c-myc gene and 
cause down-regulation of gene expression (Chernukhin et al., 2000). 
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However, in cervical carcinoma infected with HPV16, high level of c-myc 
expression was observed (Abba et al., 2004). In addition, the presence of E7 
oncoprotein was tightly associated with increased level of c-myc expression compare 
to normal cells (Oh et al., 2001; Gewin and Galloway, 2001; Lui et al., 2007). Then, 
Balakrishnan (2008) had found that the HPV16/18 E7 complex was interacting with 
CTCF, and dissociates Yb-1 from CTCF/Yb-1 complex on the c-myc promoter as 
illustrated in Figure 1.9.  Before analysing the interaction between these complexes, 
the interaction of HPV16 and HPV18 E7 with CTCF/Yb-1 were analysed 
individually.  When HPV16 E7 was introduced, it forms binding of CTCF-Zn 
domain and dissociate Yb-1 from the CTCF/Yb-1 complex as illustrated in Figure 
1.7. In other hand, HPV18 E7 was found to bind Yb-1 without disrupting the 
CTCF/Yb-1 complex as illustrated in Figure 1.8. These interactions suggested the 
release of Yb-1 might induce the expression of c-myc gene thus contribute towards 
the enhancement of cell proliferation and formation of carcinoma cells. 
 
 
 
 
 
 
 
 
